Loading
Latest filing published 29 Sept 2026 for RAC, €28k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Daniel Tillett on record concern Racura Oncology Ltd, in the capacity of senior executive. We count 7 filings; the first trade dates from 7 May 2026 and the latest from 29 September 2026.
No open-market sale appears; the market trades are 1 purchase worth €28k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The record was last updated on 29 September 2026 with an open-market purchase (€28k) in Racura Oncology Ltd. Publication is fast: at least half of the trades appear on ASX on the same day. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from ASX. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations